ide-cel 早期复发后 BCMA 靶向双特异性抗体治疗结局不佳:一项法国真实世界研究 Poor outcomes with BCMA-targeting bispecific antibodies following early relapse from ide-cel: a real-world French study. PubMed 2026/02/24 发表Blood AdvQ1 · IF 7.7(JCR 2025) 靶点:CD38靶点:BCMA靶点:GPRC5D技术:CAR-T技术:双特异性抗体多发性骨髓瘤
双特异性抗体在多发性骨髓瘤中的演进 The evolution of bispecific antibodies in multiple myeloma. PubMed 2026/02/01 发表Chin Clin OncolQ3 · IF 2.7(JCR 2025) 靶点:CD20靶点:CD38靶点:BCMA技术:双特异性抗体多发性骨髓瘤B细胞淋巴瘤淋巴瘤
多发性骨髓瘤靶向免疫治疗新前沿的潜力抗原 Promising Antigens for the New Frontier of Targeted Immunotherapy in Multiple Myeloma. PubMed 2021/12/06 发表Cancers (Basel)Q2 · IF 4.8(JCR 2025) 靶点:CD38靶点:BCMA靶点:GPRC5D技术:CAR-T技术:双特异性抗体多发性骨髓瘤